Benitec Biopharma to Participate in Upcoming Investor Conferences in December
November 26, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
November 14, 2024 16:30 ET
|
Benitec Biopharma Inc.
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a...
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
November 04, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Announces Updated Investor Webcast Information
October 14, 2024 06:00 ET
|
Benitec Biopharma Inc.
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been...
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
October 12, 2024 06:30 ET
|
Benitec Biopharma Inc.
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow...
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
September 26, 2024 16:30 ET
|
Benitec Biopharma Inc.
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study...
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
September 18, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
September 17, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
July 15, 2024 06:00 ET
|
Benitec Biopharma Inc.
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the...
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
July 01, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...